Dopamine Dysfunction in Depression: Application of Texture Analysis to Dopamine Transporter Single-photon Emission Computed Tomography Imaging

Overview

Journal Transl Psychiatry

Specialties Psychiatry
Public Health

Date 2022 Aug 3

PMID 35922402

Authors

Takehiro Tamura

Genichi Sugihara

Kyoji Okita

Yohei Mukai

Hiroshi Matsuda

Hiroki Shiwaku

Shunsuke Takagi

Hiromitsu Daisaki

Ukihide Tateishi

Hidehiko Takahashi

Affiliations

Soon will be listed here.

Abstract

Dopamine dysfunction has been associated with depression. However, results of recent neuroimaging studies on dopamine transporter (DAT), which reflect the function of the dopaminergic system, are inconclusive. The aim of this study was to apply texture analysis, a novel method to extract information about the textural properties of images (e.g., coarseness), to single-photon emission computed tomography (SPECT) imaging in depression. We performed SPECT using I-ioflupane to measure DAT binding in 150 patients with major depressive disorder (N = 112) and bipolar disorder (N = 38). The texture features of DAT binding in subregions of the striatum were calculated. We evaluated the relationship between the texture feature values (coarseness, contrast, and busyness) and severity of depression, and then examined the effects of medication and diagnosis on such relationship. Furthermore, using the data from 40 healthy subjects, we examined the effects of age and sex on the texture feature values. The degree of busyness of the limbic region in the left striatum linked to the severity of depression (p = 0.0025). The post-hoc analysis revealed that this texture feature value was significantly higher in both the severe and non-severe depression groups than in the remission group (p = 0.001 and p = 0.028, respectively). This finding remained consistent after considering the effect of medication. The effects of age and sex in healthy individuals were not evident in this texture feature value. Our findings imply that the application of texture analysis to DAT-SPECT may provide a state-marker of depression.

Citing Articles

Agomelatine as adjunctive therapy with SSRIs or SNRIs for major depressive disorder: a multicentre, double-blind, randomized, placebo-controlled trial.

Ju Y, Ou W, Chen H, Yang L, Long Y, Liang H BMC Med. 2025; 23(1):137.

PMID: 40038707 PMC: 11881269. DOI: 10.1186/s12916-025-03951-0.

Indicative biomarkers of Lewy body disease with oral sensory hallucinations in the older people.

Matsui H, Tamura T, Okamura T, Sugihara G, Furuta K, Omori Y PCN Rep. 2024; 3(1):e171.

PMID: 38868468 PMC: 11114429. DOI: 10.1002/pcn5.171.

Case report: Recurring and treatment-resistant depression in acquired hepatocerebral degeneration due to a congenital portosystemic shunt.

Tamura T, Takagi S, Hayakawa A, Oyama J, Fujino J, Shiwaku H Front Psychiatry. 2024; 15:1402695.

PMID: 38716114 PMC: 11074956. DOI: 10.3389/fpsyt.2024.1402695.

Unlocking the Potential of High-Quality Dopamine Transporter Pharmacological Data: Advancing Robust Machine Learning-Based QSAR Modeling.

Lee K, Won S, Oyinloye P, Shi L bioRxiv. 2024; .

PMID: 38558976 PMC: 10979915. DOI: 10.1101/2024.03.06.583803.

Gait disorders in unipolar and bipolar depression.

Bogdanova D Heliyon. 2023; 9(5):e15864.

PMID: 37305515 PMC: 10256928. DOI: 10.1016/j.heliyon.2023.e15864.

References

Anand A, Barkay G, Dzemidzic M, Albrecht D, Karne H, Zheng Q . Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011; 13(4):406-13. DOI: 10.1111/j.1399-5618.2011.00936.x. View

Nestler E, Carlezon Jr W . The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006; 59(12):1151-9. DOI: 10.1016/j.biopsych.2005.09.018. View

Carlsson A . Brain neurotransmitters in aging and dementia: similar changes across diagnostic dementia groups. Gerontology. 1987; 33(3-4):159-67. DOI: 10.1159/000212870. View

Masuoka T, Tateno A, Sakayori T, Tiger M, Kim W, Moriya H . Electroconvulsive therapy decreases striatal dopamine transporter binding in patients with depression: A positron emission tomography study with [F]FE-PE2I. Psychiatry Res Neuroimaging. 2020; 301:111086. DOI: 10.1016/j.pscychresns.2020.111086. View

Eisenberg D, Kohn P, Baller E, Bronstein J, Masdeu J, Berman K . Seasonal effects on human striatal presynaptic dopamine synthesis. J Neurosci. 2010; 30(44):14691-4. PMC: 3010858. DOI: 10.1523/JNEUROSCI.1953-10.2010. View

Kish S, Shannak K, Hornykiewicz O . Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988; 318(14):876-80. DOI: 10.1056/NEJM198804073181402. View

Tziortzi A, Haber S, Searle G, Tsoumpas C, Long C, Shotbolt P . Connectivity-based functional analysis of dopamine release in the striatum using diffusion-weighted MRI and positron emission tomography. Cereb Cortex. 2013; 24(5):1165-77. PMC: 3977617. DOI: 10.1093/cercor/bhs397. View

Der-Avakian A, Markou A . The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2011; 35(1):68-77. PMC: 3253139. DOI: 10.1016/j.tins.2011.11.005. View

Shigemoto Y, Matsuda H, Kimura Y, Chiba E, Ohnishi M, Nakaya M . Voxel-based analysis of age and gender effects on striatal [I] FP-CIT binding in healthy Japanese adults. Ann Nucl Med. 2022; 36(5):460-467. DOI: 10.1007/s12149-022-01725-9. View

10.

Abi-Dargham A, Gandelman M, DeErausquin G, Zea-Ponce Y, Zoghbi S, Baldwin R . SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996; 37(7):1129-33. View

11.

Dubol M, Trichard C, Leroy C, Granger B, Tzavara E, Martinot J . Lower midbrain dopamine transporter availability in depressed patients: Report from high-resolution PET imaging. J Affect Disord. 2019; 262:273-277. DOI: 10.1016/j.jad.2019.10.041. View

12.

Pizzagalli D, Berretta S, Wooten D, Goer F, Pilobello K, Kumar P . Assessment of Striatal Dopamine Transporter Binding in Individuals With Major Depressive Disorder: In Vivo Positron Emission Tomography and Postmortem Evidence. JAMA Psychiatry. 2019; 76(8):854-861. PMC: 6495358. DOI: 10.1001/jamapsychiatry.2019.0801. View

13.

Li Z, He Y, Tang J, Zong X, Hu M, Chen X . Molecular imaging of striatal dopamine transporters in major depression--a meta-analysis. J Affect Disord. 2014; 174:137-43. DOI: 10.1016/j.jad.2014.11.045. View

14.

Innis R, Cunningham V, Delforge J, Fujita M, Gjedde A, Gunn R . Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27(9):1533-9. DOI: 10.1038/sj.jcbfm.9600493. View

15.

Matsuda H, Murata M, Mukai Y, Sako K, Ono H, Toyama H . Japanese multicenter database of healthy controls for [I]FP-CIT SPECT. Eur J Nucl Med Mol Imaging. 2018; 45(8):1405-1416. PMC: 5993845. DOI: 10.1007/s00259-018-3976-5. View

16.

Chen S, Harmon S, Perk T, Li X, Chen M, Li Y . Diagnostic classification of solitary pulmonary nodules using dual time F-FDG PET/CT image texture features in granuloma-endemic regions. Sci Rep. 2017; 7(1):9370. PMC: 5571049. DOI: 10.1038/s41598-017-08764-7. View

17.

Sohara K, Sekine T, Tateno A, Mizumura S, Suda M, Sakayori T . Multi-Atlas MRI-Based Striatum Segmentation for I-FP-CIT SPECT (DAT-SPECT) Compared With the Bolt Method and SPECT-Atlas-Based Segmentation Method Toward the Accurate Diagnosis of Parkinson's Disease/Syndrome. Front Med (Lausanne). 2021; 8:662233. PMC: 8185065. DOI: 10.3389/fmed.2021.662233. View

18.

Klein D . Endogenomorphic depression. A conceptual and terminological revision. Arch Gen Psychiatry. 1974; 31(4):447-54. DOI: 10.1001/archpsyc.1974.01760160005001. View

19.

Honkanen E, Noponen T, Hirvilammi R, Lindholm K, Parkkola R, Joutsa J . Sex correction improves the accuracy of clinical dopamine transporter imaging. EJNMMI Res. 2021; 11(1):82. PMC: 8382816. DOI: 10.1186/s13550-021-00825-3. View

20.

Zelnik N, Angel I, Paul S, Kleinman J . Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol. 1986; 126(1-2):175-6. DOI: 10.1016/0014-2999(86)90758-2. View